As of, there are three oncology medications that are currently in the pipeline. These products are named as darinaparsin (ZIO-101), IL-12 DNA and indibulin (ZIO-301). The company with their partnership with Intexon, uses synthetic biology to address the unmet needs of oncology. With the use of the RheoSwitch Therapeutic System (RTS), they are able to control gene expression, thereby improving the response of the body to their injected medication.
As the world’s population balloons and as cancer plagues the existence of humanity, Ziopharm remains steadfast in their quest to vanquish the disease. They continue to invest in their research and development and hopefully by tomorrow, the panacea for all the maladies brought about by cancer will be put to an end.